公开(公告)号：EP1945228B2

公开(公告)日：2014-11-05

申请号：EP05856927.8

申请日：2005-10-26

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN, James, D. ,  MOSHER, Gerold, L. ,  HECKER, Douglas, B.

IPC分类号： A61K31/724 ,  A61K31/715 ,  A61K47/40 ,  A61K47/14 ,  A61K47/20

CPC分类号： C08B37/0012 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/715 ,  A61K31/724 ,  A61K45/06 ,  A61K47/40 ,  B01D1/18 ,  Y10T428/2982

公开(公告)号：EP1732512B1

公开(公告)日：2017-03-22

申请号：EP05704917.3

申请日：2004-12-31

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN; James, D. ,  ZIMMERER, Rupert, O. ,  THOMPSON, Diane, O. ,  MOSHER, Gerold, L.

IPC分类号： A61K9/08

CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/46 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/57 ,  A61K31/715

公开(公告)号：EP2043599A1

公开(公告)日：2009-04-08

申请号：EP06850326.7

申请日：2006-12-19

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN, James, D. ,  ZIMMERER, Rupert, O. ,  THOMPSON, Diane, O. ,  MOSHER, Gerold, L.

IPC分类号： A61K9/00 ,  C08B37/16

CPC分类号： A61K47/6851 ,  A61K9/0078 ,  A61K31/573 ,  A61K31/58 ,  A61K31/724 ,  A61K45/06 ,  A61K47/40 ,  A61K47/61 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0015 ,  C08L5/16 ,  A61K2300/00

摘要： An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

公开(公告)号：EP1945228B1

公开(公告)日：2011-04-06

申请号：EP05856927.8

申请日：2005-10-26

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN, James, D. ,  MOSHER, Gerold, L. ,  HECKER, Douglas, B.

IPC分类号： A61K31/724 ,  A61K31/715 ,  A61K47/40 ,  A61K47/14 ,  A61K47/20

CPC分类号： C08B37/0012 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/715 ,  A61K31/724 ,  A61K45/06 ,  A61K47/40 ,  B01D1/18 ,  Y10T428/2982

摘要： A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

公开(公告)号：EP1945228A1

公开(公告)日：2008-07-23

申请号：EP05856927.8

申请日：2005-10-26

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN, James, D. ,  MOSHER, Gerold, L. ,  HECKER, Douglas, B.

IPC分类号： A61K31/724 ,  A61K31/715

CPC分类号： C08B37/0012 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/715 ,  A61K31/724 ,  A61K45/06 ,  A61K47/40 ,  B01D1/18 ,  Y10T428/2982

摘要： A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

公开(公告)号：EP3512511A1

公开(公告)日：2019-07-24

申请号：EP17851668.8

申请日：2017-09-15

申请人： Cydex Pharmaceuticals, Inc.

发明人： RAJEWSKI, Roger ,  PIPKIN, James, D. ,  MOSHER, Gerold, L.

IPC分类号： A61K31/167 ,  A61K47/40 ,  A61K9/08 ,  A61K9/19 ,  A61P25/04 ,  A61P29/00

公开(公告)号：EP1945228B9

公开(公告)日：2015-03-11

申请号：EP05856927.8

申请日：2005-10-26

申请人： CyDex Pharmaceuticals, Inc.

发明人： PIPKIN, James, D. ,  MOSHER, Gerold, L. ,  HECKER, Douglas, B.

IPC分类号： A61K31/724 ,  A61K31/715 ,  A61K47/40 ,  A61K47/14 ,  A61K47/20

CPC分类号： C08B37/0012 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/715 ,  A61K31/724 ,  A61K45/06 ,  A61K47/40 ,  B01D1/18 ,  Y10T428/2982

公开(公告)号：EP1501496B1

公开(公告)日：2011-11-30

申请号：EP03728598.8

申请日：2003-04-29

申请人： CyDex Pharmaceuticals, Inc.

发明人： MOSHER, Gerold, L. ,  JOHNSON, Karen, T. ,  GAYED, Atef, A.

IPC分类号： A61K31/343 ,  A61K31/724 ,  A61K49/00

CPC分类号： A61K49/0006 ,  A61K9/0019 ,  A61K31/343 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/6951 ,  B82Y5/00

摘要： The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parental administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared. Solutions can be made either dilutable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.

公开(公告)号：EP2152078A1

公开(公告)日：2010-02-17

申请号：EP08769199.4

申请日：2008-04-26

申请人： CyDex Pharmaceuticals, Inc.

发明人： MOSHER, Gerold, L. ,  WEDEL, Rebecca, L. ,  JOHNSON, Karen, T. ,  MACHATHA, Stephen, G. ,  COWEE, Jane, A. ,  CUSHING, Daniel, J.

IPC分类号： A01N43/42 ,  A61K31/44 ,  A61K31/715

CPC分类号： A61K31/737 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/4365 ,  A61K31/44 ,  A61K31/724 ,  A61K31/727 ,  A61K45/06 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  A61K2300/00

摘要： The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.